Enclomiphene and testosterone replacement therapy both raise testosterone. They arrive there by opposite routes, and the route determines almost everything that differs between them: fertility, testicular volume, what happens when you stop, and which men the therapy can work for at all.
The comparison is also asymmetric in a way the marketing rarely makes clear. One of these has approved products, published labelling, and decades of clinical data. The other has neither an approved product nor any trial running beyond 16 weeks.
The Verdict
What enclomiphene actually is
Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator used in fertility medicine for decades. Clomiphene as normally supplied is a mixture of two isomers with different properties. Enclomiphene is the isomer responsible for raising gonadotropins, isolated from the mixture.
Its action is on the feedback loop rather than on the hormone itself. Testosterone converts to estradiol, and estradiol signals the hypothalamus and pituitary to slow production. Blocking that signal makes the pituitary read the system as under-supplied, so it releases more LH and FSH. LH drives testosterone production in the Leydig cells. FSH drives sperm production in the Sertoli cells. Both rise together, which is the mechanistic reason fertility is preserved.
| Enclomiphene | Testosterone replacement | |
|---|---|---|
| Where it acts | Hypothalamus and pituitary. Blocks estrogen negative feedback so LH and FSH rise | Directly replaces circulating testosterone from an external source |
| What happens to LH and FSH | Both rise. FSH is the signal that keeps sperm production running | Both fall, often to undetectable, because the axis reads the external supply as sufficient |
| Source of the testosterone | The testes, stimulated to produce more | The gel, injection, cream, or pellet |
| Effect on testicular volume | Preserved, since the testes stay stimulated | Shrinkage is common with sustained use |
| Effect on fertility | Sperm concentration held or increased in the trials | Sperm production suppressed, frequently to a marked degree |
| Works in primary hypogonadism | No. The testes must be capable of responding | Yes. The mechanism does not depend on testicular function |
The regulatory status
No FDA-approved enclomiphene product exists. Repros Therapeutics ran the drug through Phase III as Androxal, and the FDA issued a Complete Response Letter in 2015. The programme did not result in an approval, and none has been granted since.
Everything sold today is compounded. A compounding pharmacy prepares the medication against a prescription, and compounded preparations sit outside the FDA approval process. They are not reviewed for safety, efficacy, or quality, and there is no approved labelling that establishes dosing, contraindications, or a monitoring schedule. Platforms selling compounded enclomiphene carry this disclosure, usually in small type at the bottom of the page.
This matters practically rather than just legally. Potency and purity depend on the individual pharmacy. There is no approved package insert to check an interaction against. And because approval never arrived, the long-term safety data that ordinarily accumulates through post-marketing surveillance does not exist.
What the trials measured
| Study | Design | Result |
|---|---|---|
| ZA-301 and ZA-302 | 16 weeks, men 18–60 with secondary hypogonadism, BMI 25–42 | Both met the primary endpoint of raised morning total testosterone versus placebo. In ZA-302, 73.3% of men on the lower dose arm reached above 300 ng/dL, with mean total testosterone moving from roughly 220 to 430 ng/dL |
| ZA-304 and ZA-305, reported by Kim and colleagues in BJU International, 2016 | Double-blind, placebo-controlled, overweight men 18–60 with secondary hypogonadism, compared against topical testosterone gel | Sperm concentration rose 12–15% in the enclomiphene arms and fell 33–57% in the gel arms. Testosterone rose comparably in both |
| Wiehle and colleagues, BJU International, 2013 | Pharmacodynamic and pharmacokinetic study in secondary hypogonadism | Established the dose-response relationship and confirmed LH and FSH rise alongside testosterone |
| What no trial has reported | Trials ran to 16 weeks | No published data on fracture, cardiovascular events, mortality, or any other hard outcome. No head-to-head trial beyond a few months |
Read across these and the pattern is consistent. Enclomiphene reliably raises testosterone into the normal range in men with secondary hypogonadism, does it while raising rather than suppressing gonadotropins, and holds sperm concentration where testosterone gel reduces it substantially. The trials are not large, and they are short.
The gap worth naming is outcomes. Every published endpoint is a laboratory value or a symptom score. No trial has reported fracture rates, cardiovascular events, or mortality, and none has run long enough to. Testosterone replacement, whatever its drawbacks, has been studied against hard endpoints in large populations. That asymmetry does not make enclomiphene unsafe. It means the comparison is between a therapy with known long-term data and one without.
Fertility is usually the deciding variable
For men who want to preserve fertility, the evidence points clearly in one direction. Exogenous testosterone suppresses LH and FSH, and without FSH signalling, spermatogenesis falls. This is well enough established that testosterone is studied as a male contraceptive. Recovery after stopping is usual but can take many months, and is not guaranteed.
Enclomiphene raises FSH instead. In the comparative trials, sperm concentration rose modestly in the enclomiphene arms while falling by a third to a half in the gel arms, at similar testosterone increases. Our page on TRT and fertility covers the suppression side in more detail, including the hCG and hMG protocols used to maintain or restore production in men already on testosterone.
If fertility is not a consideration, this advantage carries much less weight, and the comparison shifts toward the approved-product question.
Side by side
| Criterion | Enclomiphene | Testosterone replacement |
|---|---|---|
| Regulatory status | No FDA-approved product. Supplied by compounding pharmacies | Multiple FDA-approved formulations with published labelling |
| Evidence depth | Phase II and III trials to 16 weeks, consistent on testosterone and sperm endpoints | Decades of use, plus large trials including cardiovascular safety data |
| Fertility preservation | The clearest documented advantage | Suppresses spermatogenesis in most men who use it |
| Requires a working testis | Yes | No |
| Administration | Oral, once daily in the trial protocols | Injection, gel, cream, or implanted pellet |
| Verdict | The option built around keeping the axis running, with a short evidence horizon and no approved product behind it | The option with regulatory approval and long-term data, at the cost of suppressing your own production |
When enclomiphene fits the situation: secondary hypogonadism confirmed on LH and FSH, fertility that matters now or later, a preference for oral administration, and a clinician willing to monitor a compounded medication properly.
When testosterone replacement fits better: primary hypogonadism, no fertility consideration, a preference for an approved product with published labelling, or a situation where cost favours a conventional generic prescription.
What monitoring looks like
Both therapies need laboratory follow-up, and the workup that precedes either is the same. What follows is what the published protocols and standard endocrine practice cover, as background for a conversation with a clinician rather than a plan to run yourself.
| Test | What it establishes | The detail that gets missed |
|---|---|---|
| Baseline total and free testosterone with SHBG | Establishes whether testosterone is genuinely low on two morning draws | A single low reading is not a diagnosis. Levels vary substantially by time of day and between draws |
| LH and FSH | Separates secondary from primary hypogonadism | This is the test that determines whether enclomiphene can work at all |
| Estradiol | Rises alongside testosterone on this mechanism | Sensitive assay required. Standard immunoassays read poorly at male concentrations |
| Prolactin, and a pituitary workup if indicated | Screens for a treatable cause of secondary hypogonadism | Elevated prolactin changes the diagnosis rather than the drug choice |
| Semen analysis if fertility is a consideration | Establishes the baseline the therapy is meant to protect | Without a baseline, a later result cannot be interpreted |
| Haematocrit and PSA where appropriate | Standard monitoring on any therapy that raises testosterone | Discuss thresholds and frequency with the prescribing clinician |
Across the physician-led platforms we assess on one rubric, the panel depth at intake is where programmes separate most visibly. Several sell an enclomiphene protocol on an intake panel that includes total testosterone but not LH and FSH, which is the pair that determines whether the drug has a mechanism to act on in that patient. Our TRT clinic comparison scores panel depth and oversight directly, and is Maximus worth it covers one such programme in detail.
Frequently Asked Questions
Is enclomiphene FDA approved?
No. There is no FDA-approved enclomiphene product. Repros Therapeutics developed enclomiphene citrate as Androxal for secondary hypogonadism and received a Complete Response Letter from the FDA in 2015, and no approval has followed. Products currently sold are compounded, meaning a pharmacy prepares them to a prescription. Compounded medications are not evaluated by the FDA for safety, efficacy, or quality, and telehealth platforms selling them are required to say so.
Is enclomiphene as effective as TRT for raising testosterone?
In the published trials the two produced comparable increases in total testosterone over 16 weeks. In the trials that compared enclomiphene against topical testosterone gel directly, testosterone rose similarly in both arms. The difference is not the size of the increase but where the testosterone comes from and what happens to the rest of the axis. Effectiveness beyond a few months has not been reported.
Does enclomiphene protect fertility?
The trial evidence supports it, and this is the strongest claim the drug has. In the studies reported by Kim and colleagues, sperm concentration rose 12–15% in the enclomiphene arms while falling 33–57% in the testosterone gel arms over the same period. The mechanism explains why: enclomiphene raises FSH, which drives sperm production, whereas external testosterone suppresses it. Anyone weighing this should have a baseline semen analysis before starting anything.
Who is enclomiphene not suitable for?
Men with primary hypogonadism, where the testes themselves cannot produce testosterone. The drug works by increasing the signal from the pituitary, so it requires testes capable of responding. LH and FSH separate the two situations: raised LH and FSH with low testosterone indicates primary hypogonadism, and no amount of additional signal will help. This is why the diagnostic workup precedes any discussion of which therapy fits.
What are the reported side effects?
The trials reported headache, nausea, hot flushes, and mood changes among the more common events, along with rising estradiol, which is expected given the mechanism. Visual disturbance is a recognised class effect of selective estrogen receptor modulators and is a reason to stop and seek medical review. Because the published trials ran to 16 weeks, the side effect profile beyond that period is not established. Discuss the full profile with a clinician rather than a platform intake form.
How does the cost compare to TRT?
Compounded enclomiphene through a telehealth platform generally runs in the same monthly range as a physician-led TRT programme, with the medication bundled into a subscription that also covers labs and consults. Generic injectable testosterone bought through a conventional pharmacy is usually the cheapest option by a wide margin, since it is an approved generic. The subscription structure is where the cost difference sits, not the molecule.
Related
- Does TRT cause infertility? — the suppression mechanism and what restores production
- TRT injections vs cream vs pellets — comparing the delivery routes
- TRT side effects and risks — what monitoring is meant to catch
- Men's hormone panel — what to test and how to read it
- Free vs total testosterone — which number the diagnosis rests on
- Signs of low testosterone — the symptom picture, and what else explains it